Dr. Daqing Wu

Associate Professor, Biochemistry and Molecular Biology, Molecular Oncology and Biomarkers Program, Georgia Cancer Center, Augusta University

“Drug Repurposing for Chemoresistant Prostate Cancer”

Wednesday, Nov. 15, 2017
11:00 AM | 201 PS

Dr. Wu’s laboratory aims to understand the biology of tumor metastasis and develop effective prevention and treatment for this lethal disease.

Docetaxel chemoresistance remains a major obstacle in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Dr. Wu’s laboratory has developed a novel high-throughput screening (HTS) platform for the discovery of effective inhibitors of chemoresistant mCRPC. Several FDA-approved non-cancer drugs have been identified as potential leads to overcome docetaxel resistance and treat mCRPC. They have performed mechanistic studies and animal experiments to validate the anticancer activities of these candidates, which can be promptly repurposed as novel drugs to treat chemoresistant mCRPC and improve clinical outcomes in patients.